Lynette Purdue

2.0k total citations
17 papers, 746 citations indexed

About

Lynette Purdue is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Lynette Purdue has authored 17 papers receiving a total of 746 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Infectious Diseases, 10 papers in Virology and 6 papers in Epidemiology. Recurrent topics in Lynette Purdue's work include HIV Research and Treatment (10 papers), HIV/AIDS drug development and treatment (9 papers) and HIV/AIDS Research and Interventions (6 papers). Lynette Purdue is often cited by papers focused on HIV Research and Treatment (10 papers), HIV/AIDS drug development and treatment (9 papers) and HIV/AIDS Research and Interventions (6 papers). Lynette Purdue collaborates with scholars based in United States, Zimbabwe and Zambia. Lynette Purdue's co-authors include Lynne Mofenson, Paul Palumbo, Michael D. Hughes, Patrick Jean‐Philippe, Werner Schimana, Susan H. Eshleman, Linda Millar, Mark F. Cotton, Portia Kamthunzi and H. Benjamin and has published in prestigious journals such as New England Journal of Medicine, Clinical Infectious Diseases and The Journal of Infectious Diseases.

In The Last Decade

Lynette Purdue

17 papers receiving 725 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lynette Purdue United States 15 572 444 168 140 96 17 746
Dorella Bricalli Italy 13 430 0.8× 428 1.0× 173 1.0× 343 2.5× 152 1.6× 15 719
Michael Wohlfeiler United States 14 758 1.3× 637 1.4× 280 1.7× 209 1.5× 107 1.1× 31 1.1k
Jussara Silveira Brazil 14 522 0.9× 440 1.0× 149 0.9× 94 0.7× 41 0.4× 32 641
Zacarias J da Silva Guinea-Bissau 14 346 0.6× 349 0.8× 141 0.8× 45 0.3× 180 1.9× 15 577
Lars Moberg Sweden 10 348 0.6× 472 1.1× 218 1.3× 55 0.4× 168 1.8× 15 641
Carrie Ziemniak United States 14 894 1.6× 898 2.0× 207 1.2× 163 1.2× 98 1.0× 19 1.0k
Catherine Fagard France 18 865 1.5× 847 1.9× 184 1.1× 99 0.7× 157 1.6× 33 1.0k
Joe Eron United States 9 509 0.9× 398 0.9× 224 1.3× 116 0.8× 35 0.4× 12 703
Winai Ratanasuwan Thailand 16 808 1.4× 594 1.3× 257 1.5× 144 1.0× 24 0.3× 38 957
Johannes Viljoen South Africa 14 373 0.7× 326 0.7× 244 1.5× 52 0.4× 47 0.5× 21 558

Countries citing papers authored by Lynette Purdue

Since Specialization
Citations

This map shows the geographic impact of Lynette Purdue's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lynette Purdue with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lynette Purdue more than expected).

Fields of papers citing papers by Lynette Purdue

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lynette Purdue. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lynette Purdue. The network helps show where Lynette Purdue may publish in the future.

Co-authorship network of co-authors of Lynette Purdue

This figure shows the co-authorship network connecting the top 25 collaborators of Lynette Purdue. A scholar is included among the top collaborators of Lynette Purdue based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lynette Purdue. Lynette Purdue is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Samson, Pearl, Edmund V. Capparelli, Carolyn Bolton‐Moore, et al.. (2019). Establishing Dosing Recommendations for Efavirenz in HIV/TB-Coinfected Children Younger Than 3 Years. JAIDS Journal of Acquired Immune Deficiency Syndromes. 81(4). 473–480. 2 indexed citations
2.
Benson, Constance A., Janet W. Andersen, Bernard Macatangay, et al.. (2018). Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus–Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy. Clinical Infectious Diseases. 67(11). 1712–1719. 21 indexed citations
3.
Bolton‐Moore, Carolyn, Edmund V. Capparelli, Pearl Samson, et al.. (2017). CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3–36 months with HIV infection. AIDS. 31(8). 1129–1136. 17 indexed citations
4.
Jacobson, Jeffrey M., Steven E. Bosinger, Minhee Kang, et al.. (2016). The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1. AIDS Research and Human Retroviruses. 32(7). 636–647. 28 indexed citations
5.
Jacobson, Jeffrey M., Hongying Wang, Rebeka Bordi, et al.. (2014). A Randomized Controlled Trial of Palifermin (Recombinant Human Keratinocyte Growth Factor) for the Treatment of Inadequate CD4+ T-Lymphocyte Recovery in Patients with HIV-1 Infection on Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 66(4). 399–406. 14 indexed citations
6.
Violari, Avy, Jane C. Lindsey, Michael D. Hughes, et al.. (2012). Nevirapine versus Ritonavir-Boosted Lopinavir for HIV-Infected Children. New England Journal of Medicine. 366(25). 2380–2389. 150 indexed citations
7.
Palumbo, Paul, Jane C. Lindsey, Michael D. Hughes, et al.. (2010). Antiretroviral Treatment for Children with Peripartum Nevirapine Exposure. New England Journal of Medicine. 363(16). 1510–1520. 172 indexed citations
8.
Chadwick, Ellen G., Jorge Pinto, Ram Yogev, et al.. (2009). Early Initiation of Lopinavir/Ritonavir in Infants Less Than 6 Weeks of Age. The Pediatric Infectious Disease Journal. 28(3). 215–219. 44 indexed citations
9.
Gandhi, Rajesh T., David O’Neill, Ronald J. Bosch, et al.. (2009). A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine. 27(43). 6088–6094. 67 indexed citations
10.
Winter, Harland S., James M. Oleske, Michael D. Hughes, et al.. (2009). Randomized Controlled Trial of Feeding a Concentrated Formula to Infants Born to Women Infected by Human Immunodeficiency Virus. Journal of Pediatric Gastroenterology and Nutrition. 49(2). 222–232. 4 indexed citations
11.
Bryson, Yvonne J., Mark Mirochnick, Alice Stek, et al.. (2008). Pharmacokinetics and Safety of Nelfinavir When Used in Combination with Zidovudine and Lamivudine in HIV-Infected Pregnant Women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353. HIV Clinical Trials. 9(2). 115–125. 35 indexed citations
12.
Jacobson, Jeffrey M., R. Pat Bucy, John Spritzler, et al.. (2006). Evidence That Intermittent Structured Treatment Interruption, but Not Immunization with ALVAC‐HIV vCP1452, Promotes Host Control of HIV Replication: The Results of AIDS Clinical Trials Group 5068. The Journal of Infectious Diseases. 194(5). 623–632. 66 indexed citations
13.
Wallis, Robert S., Robert C. Kalayjian, Jeffrey M. Jacobson, et al.. (2003). A Study of the Immunology, Virology, and Safety of Prednisone in HIV-1–Infected Subjects with CD4 Cell Counts of 200 to 700 mm−3. JAIDS Journal of Acquired Immune Deficiency Syndromes. 32(3). 281–286. 39 indexed citations
14.
Church, Joseph A., Coleen K. Cunningham, Michael Hughes, et al.. (2002). Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children. The Pediatric Infectious Disease Journal. 21(7). 653–659. 32 indexed citations
15.
Stiehm, E. Richard, Courtney V. Fletcher, Lynne Mofenson, et al.. (2000). Use of Human Immunodeficiency Virus (HIV) Human Hyperimmune Immunoglobulin in HIV Type 1–Infected Children (Pediatric AIDS Clinical Trials Group Protocol 273). The Journal of Infectious Diseases. 181(2). 548–554. 21 indexed citations
16.
Hughes, Walter T., Jerry L. Shenep, John H. Rodman, et al.. (2000). Single-Dose Pharmacokinetics and Safety of the Oral Antiviral Compound Adefovir Dipivoxil in Children Infected with Human Immunodeficiency Virus Type 1. Antimicrobial Agents and Chemotherapy. 44(4). 1041–1046. 17 indexed citations
17.
Hughes, Walter, Alejandro Dorenbaum, Ram Yogev, et al.. (1998). Phase I Safety and Pharmacokinetics Study of Micronized Atovaquone in Human Immunodeficiency Virus-Infected Infants and Children. Antimicrobial Agents and Chemotherapy. 42(6). 1315–1318. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dorella Bricalli Breakdown of academic impact, for papers by Michael Wohlfeiler Breakdown of academic impact, for papers by Jussara Silveira Breakdown of academic impact, for papers by Zacarias J da Silva Breakdown of academic impact, for papers by Lars Moberg Breakdown of academic impact, for papers by Carrie Ziemniak Breakdown of academic impact, for papers by Catherine Fagard Breakdown of academic impact, for papers by Joe Eron Breakdown of academic impact, for papers by Winai Ratanasuwan Breakdown of academic impact, for papers by Johannes Viljoen
Rankless by CCL
2026